Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"LFB","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LFB Announces FDA Approval of SEVENFACT for the Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novoseven\u00ae Recommended for Approval for the Treatment of Severe Postpartum Haemorrhage by the European Medicines Agency","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals for Coagulation Factor Viia Recombinant

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            In the primary analysis, fewer women in the NovoSeven® arm (21 vs 35) underwent additional medical procedures, such as ligation and embolisation, to stop the bleeding, corresponding to a 40% relative reduction in risk compared to standard of care.

            Lead Product(s): Eptacog Alfa

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NovoSeven

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            LFB

            Contact Supplier
            • Development Update

            Details:

            An exclusive license for the commercialization of the product in the USA and Canada has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.

            Lead Product(s): Eptacog Alfa

            Therapeutic Area: Genetic Disease Product Name: Sevenfact

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: HEMA Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY